Allt inom Corporate Information

Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan

Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes continues dose escalation according to plan with their long-acting depot formulation of the GLP-1 analog liraglutide.

Nanexa appoints new Chief Financial Officer

Nanexa AB (publ) today announces that Cecilia Danckwardt-Lillieström will take over as Chief Financial Officer as of September 1, 2024, as the current CFO Björn Svanström has chosen to leave the company.